Akba stock analysis 00. 71 in both April 2020 and June 2020 before dropping to a 52-week low of $2. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Analysts can issue or update a rating at any time. 50, significantly above the current trading price of $1. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. 50 and a high estimate of 8. 13, with a low estimate of 2. View real-time stock prices and stock quotes for a full financial overview. The analytics used are: Moving Average Price Change Percent Change Average Volume. Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease. P. 20% from the prior close of $5. Considering data from situations where AKBA advanced for three days, in of 270 cases, the price rose further within the following month. Intraday. Akebia Therapeutics stock forecast report. That is a compound annual growth rate of -1. stock information by Barron's. 32% from the current stock price of 26. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry Aug 02. Arce forecasts that the biopharmaceutical company NasdaqCM:AKBA Earnings and Revenue Growth November 9th 2024 After the latest results, the three analysts covering Akebia Therapeutics are now predicting revenues of US$179. See the latest Akebia Therapeutics Inc stock price (AKBA:XNAS), related news, Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Stock Analysis. Is AKBA stock a good investment in 2025? According to current analyst ratings, AKBA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. 8 million. Create real-time notifications to follow any changes in the live stock price. S. . 28% one Akebia Therapeutics (AKBA) shares rose on Monday after H. 5 represents a 50. Financial Analyst The financial results reported by Akebia Therapeutics, particularly the net product revenue from Auryxia, represent a stable revenue stream that is crucial for the company's operations. Revenue, EPS, net income, earnings, key ratios, debt-equity, and profit margins. This compares to loss of $0. TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 ; Period Ending. We are a leader in the renal community – a fully integrated biopharmaceutical company with #akba #akebia #akebiatherapeutics@satyajitdasgupta--------------------------------------------------------------------🔔PLEASE LIKE, SHARE & SUBSCRIBE THE CH View Our Latest Analysis on Akebia Therapeutics. 89, which is an increase of 15. 33 over the prior 15 months. 73 to a day high of $1. View the latest Akebia Therapeutics Inc. 48. In the past 30 days, 2024 earnings estimates for Roche have improved from $2. Insiders Ownership 2. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. 1. 14% of them. technincal analysis shows the Since March 20, 2014, Akebia Therapeutics's market cap has decreased from $488. 76% in the last 52 weeks. 38 or 7. Interactive Chart for Akebia Therapeutics, Inc. Choose from a list of different historical perspectives such as intraday stock behavior, gap up moves, gap down moves, large percentage moves and block trades. 09%. (AKBA), analyze all the data with a huge range of indicators. View AKBA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. / dr AKEBIA THERAPEUTICS, INC. 79 to $1. analyst ratings, historical stock prices, earnings estimates & actuals. Find everything from its Valuation, Future Growth, Past Performance and more. For example, a 9-period moving average is the average of the Interactive Chart for AKBA Feb 2025 1. Akebia Ther () Stock Market info Recommendations: Buy or sell Akebia Ther stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akebia Ther share forecasts, stock quote and buy / sell signals below. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® A high-level overview of Akebia Therapeutics, Inc. However, analysts frequently give ratings around the time a company reports quarterly earnings. Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in AKBA over the next 72 hours. This is a good sign as it is always nice to have a liquid stock. 89% : Akebia Therapeutics: ZTS : 176. 61%. 00 to $7. 05. It has now fallen 4 days in a row. 18 M. Compared to the current market price of 1. 2. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Each analyst's rating is normalized to a standardized rating Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. 89% from a day low at $1. Stock Price Target AKBA. View Akebia Therapeutics, Inc. The AKBA share price ranged from a 52-week high of $13. g. Like other stocks, AKBA shares are traded on stock exchanges, e. Akebia Therapeutics, Inc. Market Cap: US$449. The average Akebia Therapeutics stock forecast from last 6 month is $7. Akebia Therapeutics has a fifty-two week low of $0. 34 and touched a low of $5. (NASDAQ:AKBA - Free Report) by 276. com or investment advice. An analyst rating tells investors how a particular analyst feels about the stock’s price over a period of time (usually 12 to 18 months). (AKBA) Stock Price, Quote, latest community messages, chart, news and other stock related information. analyst estimates, including AKBA earnings per share estimates and analyst recommendations. 00, with forecasts ranging from $4. stock quotes reflect trades reported through Nasdaq only; comprehensive Akebia Therapeutics, Inc. 75% from the latest price. com. 2762, representing a +58. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by stock analysts at StockNews. 46% better than the analyst estimate for revenue of $55. WSJ; Analyst Ratings. 020 (1. 00 Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. 75: May-31-23: Upgrade: Piper Sandler: Neutral → Overweight: AKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) Complete Akebia Therapeutics Inc. Always conduct your own research and consider your investment goals before making investment decisions. The intrinsic value of one AKBA stock under the Base Case scenario is 4. 00: Average $ 5. Latest Stock Analysis. 50: Current Price AKBA stock analysis and financial data, including key statistics and ratios, valuations, historical price and financial performance of Akebia Therapeutics. Stock Data. 21. 04%) At close: Dec 27, 2024, 4:00 PM. and its technical analysis. 1 Wall Street analyst that have issued a 1 year AKBA price target, the average AKBA price target is $7. 80 and a 12 month high of $2. 00 in the next 12 months. Find out why I recommend selling AKBA stock. So Akebia Therapeutics, Inc. 25. Best financial portal Read Our Latest Analysis on Akebia Therapeutics Akebia Therapeutics Stock Performance. Investment ideas from the top Wall Interactive stock price chart for Akebia Therapeutics, Inc. (AKBA) stock. 08 per share a year ago. The beta is 0. 24 during the day, reaching a high of $5. 9. View Akebia Therapeutics, Inc AKBA investment & stock information. AKBA Stock Data Market Cap 437. 96 -2. Industry Track Akebia Therapeutics Inc. AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024. The highest analyst price target is $4. A list of analyst ratings for Akebia Therapeutics (AKBA) stock. 87M. Get the latest Akebia Therapeutics Inc. What Is the Akebia Ther Stock Price Today? The Akebia Ther stock price today is View Akebia Therapeutics (NASDAQ:AKBA) historical prices, past price performance, and an advanced AKBA stock chart at MarketBeat. AKBA Stock Charts Akebia Therapeutics, Inc. Includes open, high, low, close and volume. 91 and its 200-day moving average Olema Pharmaceuticals Inc (OLMA) Stock Trading Recap. The stock is currently trading at $1. Understanding Analyst Ratings You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 39 million. Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. Data is normalised which can introduce a delay from the source Despite FDA approval, Akebia's Vafseo faces skepticism in the market due to safety concerns. Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity. 94; 52-Week Range; 0. Stock Ideas; Market Outlook; Investing Strategy; @Mike9978 AKBA's stock price jumped because GSK's daprodustat approval signified that FDA was willing to approve the CKD anemia Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. The Intrinsic Value is calculated as the average of DCF and Relative values: View today's Akebia Ther stock price and latest AKBA news and analysis. How has the Akebia Therapeutics stock price performed over time. Get the latest AKBA - AKEBIA THERAPEUTICS INC quote information including top holdings and analyst ratings. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. 70%: VERTEX PHARMACEUTICALS INCORPORATED AKBA Stock Consensus Akebia Therapeutics, Inc. 68 per share. During the last trading day the stock fluctuated 2. As of November 2020, this stock provided a -36. This represents a 159. The value each AKBA share was expected to gain vs. AKBA technical analysis This gauge displays a technical analysis overview for your selected timeframe. 50: Median $ 5. us. The Akebia Therapeutics stock price fell by -2. Explore Akebia Ther (AKBA) technical analysis, including RSI, 200-day and 50-day moving averages, and key indicators. 85. dialysis patients and commenced product shipments in January 2025. Wall Street analysts predict AKBA stock could reach $5. #akba #akebia #akebiatherapeutics@satyajitdasgupta--------------------------------------------------------------------🔔PLEASE LIKE, SHARE & SUBSCRIBE THE CH Complete Akebia Therapeutics Inc. See many years of revenue, expenses and profits or losses. Sell candidate since Jan 10, 2025. 80 and a Search for a stock to start your analysis. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Wall Street analysts forecast AKBA stock price to rise over the next 12 months. New Strong Sell Stocks for November 27th. YTD; 52. Ratings range from 'Very Bullish' to 'Very Bearish'. (AKBA) stock's management team. See why I lean towards a cautious buy for AKBA stock. (AKBA. 66 which represents a slight increase of $0. Akebia Therapeutics (AKBA) reported Q3 2024 earnings per share (EPS) of-$0. Stock technical analysis with dynamic chart and Delayed Quote | Nasdaq: AKBA | Nasdaq. Akebia Therapeutics stock predict Research Akebia Therapeutics' (Nasdaq:AKBA) stock price, latest news & stock analysis. Symbol Last 3M %Chg ; AKBA : 1. On Friday, Olema Pharmaceuticals Inc (OLMA) stock saw a modest uptick, ending the day at $5. The odds of a continued upward trend are . AKBA, Akebia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. The company has a market cap of $451. This Explore the latest news, in-depth analysis, performance evaluation, and Q&A for Akebia Therapeutics, Inc. 1m in 2025. 8 analyst firms have reported ratings in the last year. 88. Analyst Ratings of AKEBIA THERAPEUTICS INC(NASDAQ:AKBA) stock. AKBA | Complete Akebia Therapeutics Inc. Wainwright & Co. 44% Based on our analysis of 6 Wall Street analysts, AKBA has a consensus that is bullish. 45M. 17% increase in average from the prior price target of the each prediction. Shares of AKBA stock traded up $0. AKBA fundamental analysis; Snowflake Score; Valuation: 2 /6Future Growth: 5 /6Past Performance: 0 /6Financial Health: 0 /6Dividends: 0 /6. AKBA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. Hold. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of AKBA | Complete Akebia Therapeutics Inc. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds. Start now and save 50% for the first 3 months Top Stocks Stock Analysis Pro. Dashboard Portfolios Watchlist Community Discover Screener. Akebia Therapeutics (NASDAQ:AKBA) shares surged over 25% premarket on Thursday after the U. Short Percent 5. 0284. The Technical Analysis page contains the results of 12 common technical analytics over different periods of time. AKBA : Akebia Therapeutics stock forecast by Wall Street Analysts. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. Shares of NASDAQ:AKBA traded down $0. View the AKBA premarket stock price ahead of the market session or assess the after hours quote. Get a real-time Akebia Therapeutics, Inc. Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. 75. Complete Akebia Therapeutics Inc. (AKBA) stock price quote with breaking news, financials, statistics, charts and more. The data used in our company analysis is from S&P Global Market Intelligence LLC. 72, so AKBA's price volatility has been lower than the market average. Following a 3-day Advance, the price is estimated to grow further. Sep Akebia Therapeutics Stock (NASDAQ: AKBA) stock price, news, charts, stock research, profile. 93 on Tuesday. Management Team : An experienced management team on the helm increases our confidence in the business – take a look at who sits on Akebia Therapeutics' board and the CEO’s background . 00 View statistical stock analysis for Akebia Therapeutics (AKBA). Free US and Canadian stock technical analysis, charts and stock screening tool utilizing technical analysis techniques such as candlestick charting, fibonacci projections, volume analysis, gaps, trends, RSI, MACD, and Stochastics. The firm Seeking Alpha's authors provide a stock rating for Akebia Therapeutics, Inc. Institutions Ownership 27. 91% for this period. ET) and the After Hours Market (4:00-8:00 p. 50, with the highest AKBA stock price forecast at $7. 5, and this show a 4. +165. Participation from Market Makers and ECNs is strictly voluntary and as a result, these An overview of all the stock ticker symbols listed. 63 million, a P/E ratio of -9. Stocks: Real-time U. The average target predicts an increase of 22. Shares of AKBA opened at $1. (AKBA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. 87 - 1. AKBA is valied quite expensively at the moment, while it does show a decent growth rate. 6,508,283 shares of the company's stock were exchanged, compared to its average volume of 2,497,784. Explore the stock pages to learn about the company's price history, financials, key stats, and more. AKBA: AI Stock Analysis of Akebia Therapeutics Inc, including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and more. Stock Analysis Pro. Barclays PLC increased its position in shares of Akebia Therapeutics, Inc. 0% increase from the past average forecast of $5. 48; Price % Chg. AKBA may be in some trouble as it scores bad on both profitability and health. 25%. 17, with a low estimate of 25 and a high estimate of 45. company's financials, related news, and its technical analysis. Franklin Covey Co NYSE:FC Find out the current price target and stock forecast for Akebia Therapeutics (AKBA) Analyst Upgrades/Downgrades. NasdaqCM:AKBA Stock Report. Watchlist Compare. 050 (2. 10, missing estimates of -$0. The following data is used in our analysis model to generate this report. Stock analysis for Akebia Therapeutics Inc (AKBA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 50 and the lowest AKBA stock price forecast at $7. Get the latest Akebia Therapeutics, Inc AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Akebia Therapeutics Price Performance. The stock opened at $5. The company's stock is available on the NASDAQ GS stock market using the AKBA ticker. 940 +0. 7 days ago - Akebia Therapeutics to Present at the 43rd Annual J. Date Brokerage Firm Analyst Previous Current; 1/14/2025: H. 5m. In November 2020, this stock was trading at $3. 01%. (AKBA) with real-time updates, full price history, technical analysis and more. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. 80 - 2. 10 per share versus the Zacks Consensus Estimate of a loss of $0. AKBA's average broker recommendation rating improved by 1. AKBA Related stocks. Financial ratios and metrics for Akebia Therapeutics (AKBA). 79. We aim to bring you long-term focused analysis driven by fundamental data. 09 in September 2020. 32% from the current stock price of 2. advanced stock charts by Barron's. See stock prices, news, financials, forecasts, charts and more. Analyst ratings, forecast, price target, upgrades and downgrades The Akebia Therapeutics Inc (AKBA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $3. Difei has covered 14 stocks with a 30. According to present data Akebia Ther's AKBA shares and potentially its market environment have been in a bullish cycle in the last 12 On Tuesday, H. Average score: Sell. 23% on the last day (Friday, 10th Jan 2025) from $1. Read why AKBA is a Hold. Detailed balance sheet for Akebia Therapeutics (AKBA), including cash, debt, assets, liabilities, and book value. 830-0. 84 USD , Akebia Therapeutics Inc is Undervalued by 59% . (NASDAQ:AKBA) shareholders will doubtless be very grateful to see the share price up 31% in the last quarter. The company has secured commercial supply contracts covering nearly 100% of U. AKBA stock has risen by 4. Akebia Therapeutics has a 12 month low of $0. 30. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The 12 analysts with 12-month price forecasts for Pfizer stock have an average target of 32. 50 expecting AKBA to rise to within 12 months (a possible 282. Sep '24 Sep 30, 2024 Dec '23 Dec 31, 2023 Dec '22 Dec 31, 2022 Dec '21 Dec 31, 2021 Dec '20 Dec 31, 2020 Dec '19 Dec 31, 2019 2018 - 2014 AKBA News. AKBA stock quote, chart and news. 65%) At close: Jan 15, 2025, 4:00 PM. StockInvest. Get much more with Stock Analysis Pro. 28. 1 day ago - Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PRNewsWire ; AKBA Stock (Akebia Therapeutics stock) AKBA STOCK PREDICTION AKBA STOCK analysis AKBA stock news today AKBA stock forecast. AKBA stock results show that Akebia Therapeutics beat on revenue for the fourth quarter of 2023. The company's stock had a trading volume of 2,388,439 shares, compared to its average volume of 2,994,756. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7. Average price target from 3 ratings: $5. Where market price tells you the price other people are willing to pay, fair value shows the value of a stock based on an analysis of the company’s actual financials (such as cash balance, revenue, operating margin, etc). (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. C. Read more here. (AKBA). Common Stock (AKBA) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq. 030 (-1. I wrote this article myself, and it expresses my own opinions. AKBA stock price. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell. Fundamental data provided by AAII's Stock Investor Pro, LSEG Data & Analytics and /I/B/E/S and are updated through the previous Complete Akebia Therapeutics Inc. Akebia Therapeutics (AKBA) has been analyzed by 4 analysts, with a consensus rating of Hold. HC Wainwright analyst E. Difei Yang is a Wall Street analyst working for Mizuho. 10 during midday trading on Monday, reaching $1. This aggregate rating is based on analysts' research of Akebia Therapeutics and is not a guaranteed prediction by Public. Includes annual, quarterly and trailing numbers with full history and charts. Is Akebia Therapeutics (AKBA) one of those stocks right now? Akebia Therapeutics (AKBA) came out with a quarterly loss of $0. In the context of all US stocks, AKEBIA THERAPEUTICS INC's average analyst price target is higher than 45. 37%. (AKBA) NASDAQ: AKBA · Real-Time Price · USD. 07. 524, and the lowest is $2. 50. 91% 1 week. 23 percent on Friday, January 10, 2025, on approximately normal volume. com from a “hold” rating to a “sell” rating in a research report issued to clients and The analysts covering Akebia Therapeutics, Inc. " The 12-month stock price forecast is $197. Options Traders Bet Big on These 3 Tech Stocks ; How to Play New Options Trading With Bitcoin ETFs; Albemarle Stock Call Options Surge: What It Means for Lithium; How to Execute the Wheel Strategy to Generate Options Income; 3 Options Strategies to Play a Stock’s Uptrend if Bullish Analyst Price Target for AKBA i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. 53 per share to $2. 78. 76% rise, e. 50, which predicts an increase of 262. RESEARCH. AKBA stock results show that Akebia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Follow $1. AKBA, $AKBA, Akebia Therapeutics Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Akebia Ther stock price live, this page displays NASDAQ AKBA stock exchange data. Collapse. Analyst Forecast. Float 207. Find the latest Akebia Therapeutics, Inc. AKBA closed down 2. 27% increase from the current price of $2. From a valuation perspective, AKBA currently trades at a relatively small market cap of $330. 0, 6 months ago from 4 wall Find the latest Akebia Therapeutics, Inc. us provides daily technical stock analysis commentaries and financial data for more than 25 000 publicly traded companies based on our calculated technical signals. 86% : Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long Investors may trade in the Pre-Market (4:00-9:30 a. Akebia Therapeutics is expected to release next earnings 2025 insights on AKBA stock fundamentals from StockInvest. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Access comprehensive stock chart, news updates, technical and fundamental analysis to empower your trading and investment decisions. But spare a thought for the long term holders, who have held Get the latest news and real-time alerts from Akebia Therapeutics, Inc. Watchlist. View now. Analyst Rating Change Price Target Change; Nov-29-23: Resumed: BTIG Research: Buy: $4: Aug-28-23: Upgrade: H. Analyst Opinion 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. STOCK/COMPANY DATA FOR AKBA . 13% from the current stock price of 2. 52 USD. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. This was 1. AKBA has an average volume of 2247080 traded shares per day. Today's Range; 1. Valuation Analysis. AKBA stock quote prices, financial information, real-time forecasts, and company news from CNN. Register for your free account today at data The 4 analysts with 12-month price forecasts for ESPR stock have an average target of 5. Akebia Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. A high-level overview of Akebia Therapeutics, Inc. The price has fallen in 5 of the last 10 days and is down by -5. Get Akebia Therapeutics Inc (AKBA. Best financial portal +951% of historical performance More than 20 Akebia Therapeutics (AKBA) advanced chart and technical analysis tool allows you to add studies and indicators such as Moving Averages (SMA and EMA), MACD, On-Balance-Volume, and more. 14 during trading hours on Thursday, reaching $2. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was-$0. 0, which is an increase of 32. Gain valuable insights from earnings call transcripts, filings, and AI-driven sentiment analysis. 10M to $409. 93. View real-time AKBA stock price and news, along with industry-best analysis. 08. the value that each AKBA share actually gained. 8800 +27. 61%) AKBA News. The fund owned 273,085 shares of the biopharmaceutical company's stock after purchasing an additional 200,482 shares during the quarter. 66% from the latest price. 950 +0. stock news by MarketWatch. NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Akebia Therapeutics, Inc. m. Wainwright: Neutral → Buy: $3. According to 21 analysts, the average rating for BA stock is "Buy. (AKBA) stock at Seeking Alpha. These AKBA gets a fundamental rating of 2 out of 10. 67%. Wainwright upgraded it, expecting FDA nod for its kidney disease candidate, vadadustat. Market Analyst Forecast. The stock price has increased by +42. 00: Low $ 4. Monitor the latest movements within the Akebia Ther real time stock price chart below. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Share your ideas and get valuable insights from the community of like minded traders and investors Akebia Therapeutics Inc. ET). 06 by 66. technincal analysis shows the buy View AKBA historical stock data and compare to other stocks, and exchanges. To do this, you need to open an account and follow a broker's procedures, then start trading. 39. 48%. Under. According to 15 analysts, the average rating for BABA stock is "Strong Buy. Morgan Healthcare Conference - PRNewsWire 22 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire 22 days ago - U. 65% upside). 92 0 Get a complete stock price history for Akebia Therapeutics, starting from its first trading day. Learn more about Akebia Therapeutics Inc's (AKBA) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs. 1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. Akebia Therapeutics plans to resubmit kidney disease drug application, while its stock outperforms S&P 500 and shows promising growth potential. 89% compared to the previous week, the month change is a 3. 94M, a decrease of -16. Analyst Price Targets 4. Q AKBA is one of the better performing stocks in the Biotechnology industry, it outperforms 81% of 561 stocks in the same industry. Analyst Ratings typically are tied into analysis of Earnings Estimates and Learn about Akebia Therapeutics, Inc. Accurate information on 100,000+ stocks and funds, including all the companies in the S&P500 index. (AKBA) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. 500 put (AKBA250221P00001500), analyze all the data with a huge range of indicators. What is the price prediction for AKBA stock? The analyst firm set a price target for $7. | Nasdaq: AKBA Akebia Therapeutics Inc. View AKBA historical stock data and compare to other stocks, and exchanges. Stock Investing News, Analysis and Tips. Explore Our Brands. According to . 56% success rate and an average return of 7. Akebia Therapeutics Inc. Should You Buy or Sell Akebia Therapeutics Stock? Get The Latest AKBA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Also, this average forecast of $7. The summary of Akebia Therapeutics, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get AKBA's stock price today. 84% 1 month. The average target predicts an increase of 132. The 1 analyst with a 12-month price forecast for Akebia Therapeutics stock has a target of 7. 1% Technical Analysis (Indicators) Bullish Trend Analysis. Seeking Alpha Akebia Ther Shares Outstanding is currently at 218. Outstanding Shares are shares of common stock of a public Akebia Ther that were purchased by investors after they were authorized and issued by the Akebia Ther to the public. See Akebia Therapeutics, Inc. View AKBA price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data. " The 12-month stock price forecast is $113. The median price target is $5. Stock Price Statistics. The firm’s 50 day moving average is $1. Rewards. Ticker Symbol: AKBA: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001517022: CUSIP Number: 00972D105: ISIN Number: US00972D1054 Detailed annual and quarterly income statement for Akebia Therapeutics (AKBA). 42%; Complete Akebia Therapeutics Inc. The Moving Average is the average price of the security or contact for the Period shown. (NASDAQ:AKBA - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. High $ 7.
gve cff fusq zjew tltak qhn djz irnepo cuuwyo akgbtnd